LEXINGTON -
The poster showcases data from the Phase 1 study of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE for the treatment of acute migraine in 26 subjects, ages 18-49 years.
Information on the poster session is as follows
Title: 'A Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of PUR3100, Novel Dry Powder Formulation of DHE for Oral Inhalation, in Healthy Adults'
Poster number: P-05
Poster available for viewing: from
Attended poster session:
The Phase 1 trial was a randomized, double-dummy, double-blinded design to assesses the safety, tolerability, and pharmacokinetics (PK) of three dose groups of inhaled PUR3100 with intravenous (IV) placebo, compared to a single dose of
The pharmacokinetic results showed a Tmax at the first time point (5 min) for all PUR3100 doses. All three doses achieved 'therapeutic' exposure levels (>1000 pg/mL). Cmax was within the desired exposure window, with similar Tmax and dose normalized AUC relative to
Dr.
About the
AHS has dedicated over 60 years to leading and serving the headache community. The American Headache Society Annual Scientific Meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain.
About
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as 'anticipates,' 'assumes,' 'believes,' 'can,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'guides,' 'intends,' 'is confident that', 'may,' 'plans,' 'seeks,' 'projects,' 'targets,' and 'would,' and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by, and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the
Contact:
Tel: 917-679-9282
Email: tim@lifesciadvisors.com
(C) 2023 Electronic News Publishing, source